There is no approved product
US medicine regulation is the work of FDA, an agency named Food and Drug Administration.
At the September 28, 2026 check, BPC-157 was not approved for any use in the US.
In the review used here, FDA also reported that no country had approved a product containing it.
Made to order does not remove the ingredient rules
Compounding means preparing a medicine to order, usually in a pharmacy.
For ordinary pharmacies, BPC-157 did not meet the federal rules for using a raw ingredient at the September 26, 2026 check.
These are legal requirements, not laboratory tests. BPC-157 has no entry setting its quality requirements in the official US pharmacy reference books. It is not an ingredient in an FDA-approved drug. It is not on FDA's extra list of ingredients pharmacies may use.
A prescription alone does not meet those legal requirements.
A withdrawn request is not permission
Groups seeking permission from FDA for pharmacy use of BPC-157 later withdrew their requests. FDA's page dated April 22, 2026 lists those requests as withdrawn.
That entry does not clear it for compounding, and the page retains FDA's concerns about possible harm.
A meeting does not settle the law
Ahead of the July 2026 advisory meeting, FDA staff opposed putting BPC-157 on the ingredient list.
By September 28, 2026, FDA had published no record saying how the committee voted.
The missing vote record does not give pharmacies permission to use BPC-157. The committee gives FDA advice. To change the list, FDA must follow the formal steps for changing a rule, including asking for public comments.